9.26
-0.56(-5.70%)
Currency In USD
Address
1330 O’Brien Drive
Fremont, CA 94025
United States of America
Phone
650 752 1300
Website
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Employees
228
First IPO Date
June 20, 2019
| Name | Title | Pay | Year Born |
| Mr. Christopher M. Hall | President, Chief Executive Officer & Director | 1.01M | 1969 |
| Mr. Stephen M. Moore J.D. | Senior Vice President, Chief Legal Officer & Corporate Secretary | 597,975 | 1972 |
| Dr. Richard Chen M.D., M.S. | Executive Vice President of R&D and Chief Medical Officer | 759,650 | 1971 |
| Mr. Aaron L. Tachibana | Chief Financial Officer & Chief Operating Officer | 781,850 | 1961 |
| Dr. Christian Haudenschild Ph.D. | Senior Vice President of Genomic Science | 0 | N/A |
| Dr. Euan Angus Ashley DPHIL, FRCP, M.D., Ph.D. | Co-Founder and Member of Clinical & Scientific Advisory Board | 0 | 1971 |
| Dr. Michael P. Snyder Ph.D. | Co-Founder and Member of Clinical & Scientific Advisory Board | 0 | N/A |
| Mr. Stephane Mouradian Ph.D. | Senior Vice President of Business Development | 0 | N/A |
| Dr. Russ B. Altman M.D., Ph.D. | Co-Founder and Member of Clinical & Scientific Advisory Board | 0 | N/A |
| Mr. Ashish Kheterpal | Senior Vice President & Chief Information Officer | 0 | N/A |
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.